Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This Phase II study will assess the efficacy, safety, and pharmacodynamics and
pharmacokinetics of 1000 mg and 1500 mg lapatinib administered once daily in patients with
relapsed adenocarcinoma of the esophagus, including tumors of the GE junction and gastric
cardia.